Premium
Drug resistance mutations and newly recognized treatment‐related substitutions in the HIV‐1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients
Author(s) -
Torti Carlo,
QuirosRoldan Eugenia,
Monno Laura,
Patroni Andrea,
Saracino Annalisa,
Angarano Gioacchino,
Tinelli Carmine,
Lo Caputo Sergio,
Tirelli Valeria,
Mazzotta Francesco,
Carosi Giampiero
Publication year - 2004
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.20142
Subject(s) - protease , virology , drug resistance , drug , gene , biology , phenotype , hiv drug resistance , hiv 1 protease , protease inhibitor (pharmacology) , genetics , lentivirus , amino acid substitution , mutation , human immunodeficiency virus (hiv) , viral disease , enzyme , pharmacology , viral load , antiretroviral therapy , biochemistry
This study aimed at identifying HIV‐1 protease amino acid changes associated with protease inhibitor (PI) exposure and susceptibility. New amino acid substitutions were correlated with the number of experienced PIs, reaching statistical significance only for those at positions 3, 44, and 74. The correspondence multivariate model demonstrated that ≥3 experienced PIs and substitutions or mutations at positions 3, 46, 54, 73, 74, and 84 were correlated with PI cross‐resistance, including resistance for lopinavir and amprenavir in this cohort of patients who were naive for these drugs. J. Med. Virol. 74:29–33, 2004. © 2004 Wiley‐Liss, Inc.